• Ioana Diana Olaru, Florian von Groote-Bidlingmaier, Jan Heyckendorf, Wing Wai Yew, Christoph Lange, and Kwok Chiu Chang.
• Division of Clinical Infectious Diseases, Research Center Borstel, German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany.
• Eur. Respir. J. 2015 Apr 1; 45 (4): 1119-31.

AbstractThe United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. Before novel drugs can find their place in the battle against drug-resistant tuberculosis, linezolid has been compassionately used with success in the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis. This review largely discusses six novel drugs that have been evaluated in phase II and III clinical trials, with focus on the clinical evidence for efficacy and safety, potential drug interactions, and prospect for using multiple novel drugs in new regimens.Copyright ©ERS 2015.

30 keywords...

hide…